Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance

Mathematical Models for Cell Migration with Real-Time Cell Cycle Dynamics

(2018) Sean T. Vittadello et al.   BIOPHYSICAL JOURNAL

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors

(2018) Julia Boshuizen et al.   NATURE MEDICINE

Cell cycle-tailored targeting of metastatic melanoma: Challenges and opportunities

(2017) Nikolas K. Haass et al.   EXPERIMENTAL DERMATOLOGY

Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma

(2017) Paola Falletta et al.   GENES & DEVELOPMENT

Epigenetics in cancer stem cells

(2017) Tan Boon Toh et al.   Molecular Cancer

The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma

(2017) Antonio Ahn et al.   MOLECULAR CANCER THERAPEUTICS

A slow-cycling subpopulation of melanoma cells with highly invasive properties

(2017) M Perego et al.   ONCOGENE

Intratumor and Intertumor Heterogeneity in Melanoma

(2017) Tomasz M. Grzywa et al.   Translational Oncology

Microenvironment-derived factors driving metastatic plasticity in melanoma

(2017) Isabella S. Kim et al.   Nature Communications

Dendritic Mesoporous Silica Nanoparticles for pH-Stimuli-Responsive Drug Delivery of TNF-Alpha

(2017) Arne Kienzle et al.   Advanced Healthcare Materials

NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF

(2017) Mitchell E. Fane et al.   EBioMedicine

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

(2016) Michael P. Smith et al.   CANCER CELL

Immune Checkpoint Therapy in Melanoma

(2016) Margaret K. Callahan   CANCER JOURNAL

Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?

(2016) Matteo S. Carlino et al.   CLINICAL CANCER RESEARCH

Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?

(2016) Sarah J. Welsh et al.   EUROPEAN JOURNAL OF CANCER

Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells

(2016) Kimberley A. Beaumont et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma

(2016) Y. Qin et al.   MOLECULAR CANCER THERAPEUTICS

sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

(2016) Amanpreet Kaur et al.   NATURE

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

(2016) I. Tirosh et al.   SCIENCE

Targeting MITF in the tolerance-phase

(2016) Imanol Arozarena et al.   Oncotarget

Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling

(2015) Eishu Hirata et al.   CANCER CELL

Tumors and Mitochondrial Respiration: A Neglected Connection

(2015) Andrea Viale et al.   CANCER RESEARCH

Genomic Classification of Cutaneous Melanoma

(2015) Rehan Akbani et al.   CELL

Complete remission of metastatic melanoma upon BRAF inhibitor treatment – what happens after discontinuation?

(2015) Henrike Tolk et al.   MELANOMA RESEARCH

Pan-cancer analysis of the extent and consequences of intratumor heterogeneity

(2015) Noemi Andor et al.   NATURE MEDICINE

Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy

(2015) Claudia Wellbrock et al.   Pigment Cell & Melanoma Research

Imaging- and Flow Cytometry-based Analysis of Cell Position and the Cell Cycle in 3D Melanoma Spheroids

(2015) Kimberley A. Beaumont et al.   Jove-Journal of Visualized Experiments

Mitochondrial oxidative stress is the achille’s heel of melanoma cells resistant to Braf-mutant inhibitor

(2015) Paola Corazao-Rozas et al.   Oncotarget

MITF in melanoma: mechanisms behind its expression and activity

(2014) Mariusz L. Hartman et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

(2014) H. Rizos et al.   CLINICAL CANCER RESEARCH

Melanoma never says die

(2014) Nikolas K. Haass et al.   EXPERIMENTAL DERMATOLOGY

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

(2014) Chong Sun et al.   NATURE

A stress-induced early innate response causes multidrug tolerance in melanoma

(2014) D Ravindran Menon et al.   ONCOGENE

Single-cell gene expression signatures reveal melanoma cell heterogeneity

(2014) M Ennen et al.   ONCOGENE

Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma

(2014) A Roesch   ONCOGENE

Real-time cell cycle imaging during melanoma growth, invasion, and drug response

(2014) Nikolas K. Haass et al.   Pigment Cell & Melanoma Research

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

(2014) Judith Müller et al.   Nature Communications

The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNF 

(2014) M. P. Smith et al.   Cancer Discovery

A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

(2014) D. J. Konieczkowski et al.   Cancer Discovery

Heterogeneous Tumor Subpopulations Cooperate to Drive Invasion

(2014) Anna Chapman et al.   Cell Reports

Cancer heterogeneity: implications for targeted therapeutics

(2013) R Fisher et al.   BRITISH JOURNAL OF CANCER

PGC1α Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress

(2013) Francisca Vazquez et al.   CANCER CELL

Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF

(2013) Rizwan Haq et al.   CANCER CELL

Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells

(2013) Alexander Roesch et al.   CANCER CELL

Molecular and cellular pathogenesis of melanoma initiation and progression

(2013) Tarik Regad   CELLULAR AND MOLECULAR LIFE SCIENCES

Vemurafenib Induces Senescence Features in Melanoma Cells

(2013) Sebastian Haferkamp et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Resistance to RAF Inhibitors Revisited

(2013) Edward Hartsough et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Human skin neural crest progenitor cells are susceptible to BRAF V600E -induced transformation

(2013) S M Kumar et al.   ONCOGENE

Melanoma’s connections to the tumour microenvironment

(2013) Johanna M. Brandner et al.   PATHOLOGY

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2

(2013) M. P. O'Connell et al.   Cancer Discovery

The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

(2013) E. M. Van Allen et al.   Cancer Discovery

A Landscape of Driver Mutations in Melanoma

(2012) Eran Hodis et al.   CELL

Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma

(2012) Michael P. Smith et al.   JNCI-Journal of the National Cancer Institute

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Systematic classification of melanoma cells by phenotype-specific gene expression mapping

(2012) Daniel S. Widmer et al.   Pigment Cell & Melanoma Research

Snail1 Mediates Hypoxia-Induced Melanoma Progression

(2011) Shujing Liu et al.   AMERICAN JOURNAL OF PATHOLOGY

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine

The proliferation rate paradox in antimitotic chemotherapy

(2011) Timothy J. Mitchison   MOLECULAR BIOLOGY OF THE CELL

A picture of Mitf in melanoma immortality

(2011) C R Goding   ONCOGENE

Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny

(2011) Y Cheli et al.   ONCOGENE

Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF

(2011) E. Feige et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Slow-Cycling Therapy-Resistant Cancer Cells

(2011) Nathan Moore et al.   STEM CELLS AND DEVELOPMENT

Microphthalmia-Associated Transcription Factor Controls the DNA Damage Response and a Lineage-Specific Senescence Program in Melanomas

(2010) Sandy Giuliano et al.   CANCER RESEARCH

A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth

(2010) Alexander Roesch et al.   CELL

PAX3 knockdown in metastatic melanoma cell lines does not reduce MITF expression

(2010) Shujie He et al.   MELANOMA RESEARCH

Moving Targets That Drive Cancer Progression

(2010) Mark Shackleton   NEW ENGLAND JOURNAL OF MEDICINE

Cancer stem cells versus phenotype-switching in melanoma

(2010) Keith S. Hoek et al.   Pigment Cell & Melanoma Research

Quiescent, Slow-Cycling Stem Cell Populations in Cancer: A Review of the Evidence and Discussion of Significance

(2010) Nathan Moore et al.   Journal of Oncology

Tumor heterogeneity: Causes and consequences

(2009) Andriy Marusyk et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Fifteen-year quest for microphthalmia-associated transcription factor target genes

(2009) Yann Cheli et al.   Pigment Cell & Melanoma Research

Melanocytes: From Morphology to Application

(2009) A. Santiago-Walker et al.   SKIN PHARMACOLOGY AND PHYSIOLOGY

In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States

(2008) K. S. Hoek et al.   CANCER RESEARCH

Wnt5A Regulates Expression of Tumor-Associated Antigens in Melanoma via Changes in Signal Transducers and Activators of Transcription 3 Phosphorylation

(2008) S. K. Dissanayake et al.   CANCER RESEARCH

Visualizing Spatiotemporal Dynamics of Multicellular Cell-Cycle Progression

(2008) Asako Sakaue-Sawano et al.   CELL

Novel MITF targets identified using a two-step DNA microarray strategy

(2008) Keith S. Hoek et al.   Pigment Cell & Melanoma Research

Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF

(2008) Claudia Wellbrock et al.   PLoS One